Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

• Status: Recruiting
• Trial end date: 2026-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen.

Participants will divided in to three groups.

• Participants who were already taking low dose antiplatelet medications.

• Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator

• Participants does not use any medications.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Navamindradhiraj University
• Treatments: Acetylcysteine; Aspirin; Clopidogrel; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.

• Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.

• Age range: 50-85 years

• Patients who have previously used antiplatelet drugs.

Exclusion Criteria:

• Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)

• Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.

• Patient with a history of intravitreal anti-VEGF injection or macular laser.

• Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.